On November 25, Gelonghui announced that shenzhen kangtai biological products (300601.SZ) revealed that its wholly-owned subsidiary Peking Minhai Biological Technology Co., Ltd. (hereinafter referred to as "Minhai Biological") has completed the preparation work for Phase I clinical trials of the 20-valent pneumococcal polysaccharide conjugate vaccine, has initiated Phase I clinical trials, and successfully completed the enrollment of the first subject recently.
The 20-valent pneumococcal polysaccharide conjugate vaccine is suitable for infants and children aged 2 months to 5 years. After vaccination with this vaccine, it can elicit an immune response in the body to prevent infectious diseases caused by 20 types of pneumococcal serotypes.
Currently, the only manufacturer of the 20-valent pneumococcal polysaccharide conjugate vaccine available overseas is pfizer; according to a search on the National Medical Products Administration website, there are currently no approved listings for the 20-valent pneumococcal polysaccharide conjugate vaccine within the country.
